another biotech flying under the radar , page-63

hi daon,

I think it is still in early stages IMO to be presented at that conference and it is for health executives
midkine has yet to be validated and celera has taken that role on board for lung cancer diagnostics. Other applications are pending.
As mentioned during my conversation with the company earlier, the treatment part of it is the big one and will be the big revenue earner.
The diagnostic part though once validated will bring in the cash flow required to proceed with the phase 1 , 2 trials and beyond. To be honest, this one is in the bottom drawer for me , but will keep evaluating its progress half yearly.
Celera has seen something in it so looks promising. think about it as P** in early stages.
cheers